Treatment Avenues for Age-Related Macular Degeneration: Breakthroughs and Bottlenecks.

Kumbhar, P; Kolekar, K; Vishwas, S; Shetti, P; Kumbar, V; Andreoli Pinto, TDJ; Paiva-Santos, AC; Veiga, F; Gupta, G; Singh, SK; Dua, K; Disouza, J; Patravale, V

Treatment Avenues for Age-Related Macular Degeneration: Breakthroughs and Bottlenecks.

Kumbhar, P Kolekar, K Vishwas, S Shetti, P Kumbar, V Andreoli Pinto, TDJ Paiva-Santos, AC Veiga, F Gupta, G Singh, SK Dua, K

Disouza, J Patravale, V

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Ageing Res Rev, 2024, pp. 102322
Issue Date:: 2024-05-07

Closed Access

	Filename	Description	Size
	Age-Related Macular Degeneration_Breakthroughs and Bottlenecks.pdf	Published version	9.64 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kumbhar, P
dc.contributor.author	Kolekar, K
dc.contributor.author	Vishwas, S
dc.contributor.author	Shetti, P
dc.contributor.author	Kumbar, V
dc.contributor.author	Andreoli Pinto, TDJ
dc.contributor.author	Paiva-Santos, AC
dc.contributor.author	Veiga, F
dc.contributor.author	Gupta, G
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Disouza, J
dc.contributor.author	Patravale, V
dc.date.accessioned	2024-05-20T11:31:18Z
dc.date.available	2024-05-03
dc.date.available	2024-05-20T11:31:18Z
dc.date.issued	2024-05-07
dc.identifier.citation	Ageing Res Rev, 2024, pp. 102322
dc.identifier.issn	1568-1637
dc.identifier.issn	1872-9649
dc.identifier.uri	http://hdl.handle.net/10453/179067
dc.description.abstract	Age-related macular degeneration (AMD) is a significant factor contributing to serious vision loss in adults above 50. The presence of posterior segment barriers serves as chief roadblocks in the delivery of drugs to treat AMD. The conventional treatment strategies use is limited due to its off-targeted distribution in the eye, shorter drug residence, poor penetration and bioavailability, fatal side effects, etc. The above-mentioned downside necessitates drug delivery using some cutting-edge technology including diverse nanoparticulate systems and microneedles (MNs) which provide the best therapeutic delivery alternative to treat AMD efficiently. Furthermore, cutting-edge treatment modalities including gene therapy and stem cell therapy can control AMD effectively by reducing the boundaries of conventional therapies with a single dose. This review discusses AMD overview, conventional therapies for AMD and their restrictions, repurposed therapeutics and their anti-AMD activity through different mechanisms, and diverse barriers in drug delivery for AMD. Various nanoparticulate-based approaches including polymeric NPs, lipidic NPs, exosomes, active targeted NPs, stimuli-sensitive NPs, cell membrane-coated NPs, inorganic NPs, and MNs are explained. Gene therapy, stem cell therapy, and therapies in clinical trials to treat AMD are also discussed. Further, bottlenecks of cutting-edge (nanoparticulate) technology-based drug delivery are briefed. In a nutshell, cutting-edge technology-based therapies can be an effective way to treat AMD.
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Ageing Res Rev
dc.relation.isbasedon	10.1016/j.arr.2024.102322
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology, 1103 Clinical Sciences, 1109 Neurosciences
dc.subject.classification	Gerontology
dc.subject.classification	3101 Biochemistry and cell biology
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	3209 Neurosciences
dc.title	Treatment Avenues for Age-Related Macular Degeneration: Breakthroughs and Bottlenecks.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1103 Clinical Sciences
utslib.for	1109 Neurosciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2024-05-20T11:31:11Z
pubs.publication-status	Published online

Abstract:

Age-related macular degeneration (AMD) is a significant factor contributing to serious vision loss in adults above 50. The presence of posterior segment barriers serves as chief roadblocks in the delivery of drugs to treat AMD. The conventional treatment strategies use is limited due to its off-targeted distribution in the eye, shorter drug residence, poor penetration and bioavailability, fatal side effects, etc. The above-mentioned downside necessitates drug delivery using some cutting-edge technology including diverse nanoparticulate systems and microneedles (MNs) which provide the best therapeutic delivery alternative to treat AMD efficiently. Furthermore, cutting-edge treatment modalities including gene therapy and stem cell therapy can control AMD effectively by reducing the boundaries of conventional therapies with a single dose. This review discusses AMD overview, conventional therapies for AMD and their restrictions, repurposed therapeutics and their anti-AMD activity through different mechanisms, and diverse barriers in drug delivery for AMD. Various nanoparticulate-based approaches including polymeric NPs, lipidic NPs, exosomes, active targeted NPs, stimuli-sensitive NPs, cell membrane-coated NPs, inorganic NPs, and MNs are explained. Gene therapy, stem cell therapy, and therapies in clinical trials to treat AMD are also discussed. Further, bottlenecks of cutting-edge (nanoparticulate) technology-based drug delivery are briefed. In a nutshell, cutting-edge technology-based therapies can be an effective way to treat AMD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/179067